Pieris Pharmaceuticals Inc. (PVLA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
125 STRAFFORD AVE WAYNE, PA 19087 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 26,400 | 59,200 | 117,764 | 70,436 | 104,154 | 128,107 | |||
| Cash and cash equivalent | 17,396 | 38,635 | 117,764 | 70,436 | 62,260 | 74,867 | |||
| Short-term investments | 8,970 | 20,534 | 41,894 | 53,240 | |||||
| Other undisclosed cash, cash equivalents, and short-term investments | 34 | 31 | |||||||
| Receivables | 6,039 | 5,810 | 3,313 | 1,706 | 6,787 | 2,701 | |||
| Deferred costs | 1,005 | 3,374 | |||||||
| Asset, held-for-sale, not part of disposal group | 2,188 | ||||||||
| Other undisclosed current assets | 4,053 | 8,414 | 6,548 | 3,579 | 3,067 | 1,200 | |||
| Total current assets: | 38,680 | 73,424 | 127,625 | 75,721 | 115,013 | 135,382 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 3,705 | 3,909 | 3,934 | ✕ | |||||
| Property, plant and equipment | 16,992 | 19,122 | 22,046 | 19,502 | 5,049 | ||||
| Other noncurrent assets | 1,369 | 2,904 | 3,309 | 3,146 | 910 | ||||
| Other undisclosed noncurrent assets | 3,436 | ||||||||
| Total noncurrent assets: | 22,066 | 25,935 | 29,289 | 26,084 | 5,959 | ||||
| TOTAL ASSETS: | 38,680 | 95,490 | 153,560 | 105,010 | 141,097 | 141,341 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 10,183 | 7,652 | 15,563 | 6,001 | 15,747 | 12,464 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 3,581 | 2,759 | ||||
| Accounts payable | 3,372 | 4,154 | 8,609 | 1,787 | 5,803 | 3,350 | |||
| Accrued liabilities | 6,811 | 3,498 | 3,373 | 1,455 | 9,944 | 9,114 | |||
| Deferred revenue | 20,824 | 25,116 | 12,627 | ✕ | |||||
| Derivative instruments and hedges, liabilities | |||||||||
| Other liabilities | |||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 35,612 | ||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | 11,256 | |||
| Other undisclosed current liabilities | 1,739 | 8,107 | 9,882 | 3,517 | |||||
| Total current liabilities: | 11,922 | 36,583 | 50,561 | 22,145 | 27,003 | 48,076 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 13,841 | 15,932 | |||||||
| Liabilities, other than long-term debt | 30,978 | 38,403 | 35,906 | 47,258 | 53,330 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 53,303 | ||
| Deferred revenue | 18,734 | 38,403 | 35,900 | ✕ | |||||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | 47,258 | |||
| Other liabilities | 6 | 27 | |||||||
| Operating lease, liability | 12,244 | 13,841 | 15,932 | ✕ | |||||
| Derivative instruments and hedges, liabilities | |||||||||
| Other undisclosed noncurrent liabilities | 15,484 | ||||||||
| Total noncurrent liabilities: | 30,978 | 52,244 | 51,838 | 62,742 | 53,330 | ||||
| Total liabilities: | 11,922 | 67,561 | 102,805 | 73,983 | 89,745 | 101,406 | |||
| Equity | |||||||||
| Equity, attributable to parent | 26,758 | 27,929 | 50,755 | 31,027 | 51,352 | 39,935 | |||
| Common stock | 98 | 74 | 72 | 56 | 55 | 54 | |||
| Additional paid in capital | 341,596 | 318,530 | 306,998 | 242,672 | 227,468 | 189,929 | |||
| Accumulated other comprehensive income (loss) | 28 | (254) | 829 | (295) | (1,995) | (2,982) | |||
| Accumulated deficit | (314,964) | (290,421) | (257,144) | (211,406) | (174,176) | (147,066) | |||
| Total equity: | 26,758 | 27,929 | 50,755 | 31,027 | 51,352 | 39,935 | |||
| TOTAL LIABILITIES AND EQUITY: | 38,680 | 95,490 | 153,560 | 105,010 | 141,097 | 141,341 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 42,810 | 25,902 | 31,418 | 29,323 | 46,279 | 29,101 | ||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 26,768 | |
| Gross profit: | 42,810 | 25,902 | 31,418 | 29,323 | 46,279 | 29,101 | ||
| Operating expenses | (72,566) | (69,376) | (83,249) | (63,244) | (73,436) | (59,932) | ||
| Operating loss: | (29,756) | (43,474) | (51,831) | (33,921) | (27,157) | (30,831) | ||
| Nonoperating income (expense) | (250) | 1,303 | 2,404 | (3,648) | 35 | 3,432 | ||
| Investment income, nonoperating | 1,651 | |||||||
| Gain (loss), foreign currency transaction, before tax | 8 | 61 | (22) | |||||
| Other nonoperating income (expense) | (250) | 1,303 | 2,404 | (3,656) | (26) | 1,803 | ||
| Interest and debt expense | ||||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 503 | 1,653 | 333 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (30,006) | (42,171) | (49,427) | (37,066) | (25,469) | (27,066) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 5,462 | 8,894 | 3,689 | |||||
| Loss from continuing operations before income taxes: | (24,544) | (33,277) | (45,738) | (37,066) | (25,469) | (27,066) | ||
| Income tax expense (benefit) | (164) | 312 | ||||||
| Loss from continuing operations: | (24,544) | (33,277) | (45,738) | (37,230) | (25,469) | (26,754) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (45,738) | (37,230) | (25,469) | (26,754) | |
| Net loss: | (24,544) | (33,277) | (45,738) | (37,230) | (25,469) | (26,754) | ||
| Other undisclosed net income attributable to parent | 1 | |||||||
| Net loss attributable to parent: | (24,543) | (33,277) | (45,738) | (37,230) | (25,469) | (26,754) | ||
| Other undisclosed net loss available to common stockholders, basic | (2,830) | |||||||
| Net loss available to common stockholders, diluted: | (24,543) | (33,277) | (45,738) | (37,230) | (28,299) | (26,754) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (24,544) | (33,277) | (45,738) | (37,230) | (25,469) | (26,754) | ||
| Other comprehensive loss | (164) | |||||||
| Comprehensive loss: | (24,544) | (33,277) | (45,738) | (37,230) | (25,469) | (26,918) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 283 | (1,083) | 1,124 | 1,700 | 987 | 1,877 | ||
| Comprehensive loss, net of tax, attributable to parent: | (24,261) | (34,360) | (44,614) | (35,530) | (24,482) | (25,041) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.